Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Share-based Compensation (2023 - 2025)

CG Oncology filings provide 3 years of Share-based Compensation readings, the most recent being $7.2 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 44.03% to $7.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.7 million, a 133.96% increase, with the full-year FY2025 number at $26.7 million, up 133.96% from a year prior.
  • Share-based Compensation hit $7.2 million in Q4 2025 for CG Oncology, down from $7.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q3 2025 to a low of $177000.0 in Q2 2023.
  • Median Share-based Compensation over the past 3 years was $2.4 million (2024), compared with a mean of $3.3 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 1168.93% in 2024 and later surged 44.03% in 2025.
  • CG Oncology's Share-based Compensation stood at $778000.0 in 2023, then skyrocketed by 541.39% to $5.0 million in 2024, then surged by 44.03% to $7.2 million in 2025.
  • The last three reported values for Share-based Compensation were $7.2 million (Q4 2025), $7.3 million (Q3 2025), and $7.0 million (Q2 2025) per Business Quant data.